This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pollock, P. M. Articles by Hayward, N. K. Search for Related Content PubMed PubMed Citation Articles by Pollock, P. M. Articles by Hayward, N. K.

Evidence for Three Tumor Suppressor Loci on Chromosome 9p Involved in Melanoma Development

Cancer Genetics Branch, National Human Genome Research Institute, NIH, Bethesda, MD 20892-4094 [P. M. P.], and Joint Experimental Oncology Program of the Queensland Institute of Medical Research, the University of Queensland, and the Queensland Cancer Fund, Queensland, 4029 Australia [J. W., N. K. H.]

Cytogenetic and loss of heterozygosity (LOH) studies have long indicated the presence of a tumor suppressor gene (TSG) on 9p involved in the development of melanoma. Although LOH at 9p has been reported in approximately 60% of melanoma tumors, only 5–10% of these tumors have been shown to carry CDKN2A mutations, raising the possibility that another TSG involved in melanoma maps to chromosome 9p. To investigate this possibility, a panel of 37 melanomas derived from 35 individuals was analyzed for CDKN2A mutations by single-strand conformation polymorphism analysis and sequencing. The melanoma samples were then typed for 15 markers that map to 9p13–24 to investigate LOH trends in this region. In those tumors demonstrating retention of heterozygosity at markers flanking CDKN2A and LOH on one or both sides of the gene, multiplex microsatellite PCR was performed to rule out homozygous deletion of the region encompassing CDKN2A. CDKN2A mutations were found in tumors from 5 patients [5 (14%) of 35], 4 of which demonstrated LOH across the entire region examined. The remaining tumor with no observed LOH carried two point mutations, one on each allele. Although LOH was identified at one or more markers in 22 (59%) of 37 melanoma tumors corresponding to 20 (57%) of 35 individuals, only 11 tumors from 9 individuals [9 (26%) of 35] demonstrated LOH at D9S942 and D9S1748, the markers closest to CDKN2A. Of the remaining 11 tumors with LOH, 9 demonstrated LOH at two or more contiguous markers either centromeric and/or telomeric to CDKN2A while retaining heterozygosity at several markers adjacent to CDKN2A. Multiplex PCR revealed one tumor carried a homozygous deletion extending from D9S1748 to the IFN- locus. In the remaining eight tumors, multiplex PCR demonstrated that the observed heterozygosity was not attributable to homozygous deletion and stromal contamination at D9S1748, D9S942, or D9S974, as measured by comparative amplification strengths, which indicates that retention of heterozygosity with flanking LOH does not always indicate a homozygous deletion. This report supports the conclusions of previous studies that at least two TSGs involved in melanoma development in addition to CDKN2A may reside on chromosome 9p.

This article has been cited by other articles:

				S. Veeriah, C. Brennan, S. Meng, B. Singh, J. A. Fagin, D. B. Solit, P. B. Paty, D. Rohle, I. Vivanco, J. Chmielecki, et al. The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers PNAS, June 9, 2009; 106(23): 9435 - 9440. [Abstract] [Full Text] [PDF]

				D. A. Solomon, J.-S. Kim, J. C. Cronin, Z. Sibenaller, T. Ryken, S. A. Rosenberg, H. Ressom, W. Jean, D. Bigner, H. Yan, et al. Mutational Inactivation of PTPRD in Glioblastoma Multiforme and Malignant Melanoma Cancer Res., December 15, 2008; 68(24): 10300 - 10306. [Abstract] [Full Text] [PDF]

				K Laud, C Marian, M F Avril, M Barrois, A Chompret, A M Goldstein, M A Tucker, P A Clark, G Peters, V Chaudru, et al. Comprehensive analysis of CDKN2A (p16INK4A/p14ARF) and CDKN2B genes in 53 melanoma index cases considered to be at heightened risk of melanoma J. Med. Genet., January 1, 2006; 43(1): 39 - 47. [Abstract] [Full Text] [PDF]

				K. Hoek, D. L. Rimm, K. R. Williams, H. Zhao, S. Ariyan, A. Lin, H. M. Kluger, A. J. Berger, E. Cheng, E. S. Trombetta, et al. Expression Profiling Reveals Novel Pathways in the Transformation of Melanocytes to Melanomas Cancer Res., August 1, 2004; 64(15): 5270 - 5282. [Abstract] [Full Text] [PDF]

				T. Ueki, A. W. Hsing, Y.-T. Gao, B.-S. Wang, M.-C. Shen, J. Cheng, J. Deng, J. F. Fraumeni Jr., and A. Rashid Alterations of p16 and Prognosis in Biliary Tract Cancers from a Population-Based Study in China Clin. Cancer Res., March 1, 2004; 10(5): 1717 - 1725. [Abstract] [Full Text] [PDF]

				B. Taback, S. J. O'Day, P. D. Boasberg, S. Shu, P. Fournier, R. Elashoff, H.-J. Wang, and D. S. B. Hoon Circulating DNA Microsatellites: Molecular Determinants of Response to Biochemotherapy in Patients With Metastatic Melanoma J Natl Cancer Inst, January 21, 2004; 96(2): 152 - 156. [Abstract] [Full Text] [PDF]

				C. M. Wong, J. M. F. Lee, T. C. M. Lau, S. T. Fan, and I. O. L. Ng Clinicopathological Significance of Loss of Heterozygosity on Chromosome 13q in Hepatocellular Carcinoma Clin. Cancer Res., July 1, 2002; 8(7): 2266 - 2272. [Abstract] [Full Text] [PDF]

				A. M. Goldstein and M. A. Tucker Genetic Epidemiology of Cutaneous Melanoma: A Global Perspective Arch Dermatol, November 1, 2001; 137(11): 1493 - 1496. [Full Text] [PDF]

				B. Taback, Y. Fujiwara, H.-J. Wang, L. J. Foshag, D. L. Morton, and D. S. B. Hoon Prognostic Significance of Circulating Microsatellite Markers in the Plasma of Melanoma Patients Cancer Res., August 1, 2001; 61(15): 5723 - 5726. [Abstract] [Full Text] [PDF]